Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Giiant pharma","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Giiant Pharma inc Announced the Closing of US$11M in Seed Financing","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Giiant Pharma inc Extended Its Seed Round With AQC Capital and CQDM to Ensure Reaching Clinical Proof-of-Concept","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Palisade Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Crohn\u2019s and Colitis Foundation","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn's and Colitis Foundation for Development of PALI-2108","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Giiant pharma

    Menu

    Giiant pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Giiant pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn's and Colitis Foundation for Development of PALI-2108

              Details:

              The proceeds will be used for the development of Palisade's lead program, PALI-2108, a microbiota-activated PDE4 inhibitor prodrug, for the treatment of moderate-to-severe ulcerative colitis.

              Lead Product(s): PALI-2108

              Therapeutic Area: Gastroenterology Product Name: PALI-2108

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Crohn’s and Colitis Foundation

              Deal Size: $0.5 million Upfront Cash: Undisclosed

              Deal Type: Funding December 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Giiant pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammator...

              Details:

              Under the agreement, Palisade wil develop, manufacture and commercialize Giiant’s proprietary targeted prodrug platform, including GT-2108, an orally administered, gut-restricted, colon-specific PDE4 inhibitor prodrug in development for patients affected by ulcerative colitis.

              Lead Product(s): GT-2108

              Therapeutic Area: Gastroenterology Product Name: GT-2108

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Palisade Bio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement September 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Giiant pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Giiant Pharma inc Extended Its Seed Round With AQC Capital and CQDM to Ensure Reaching Clinical Proof-of-Concept

              Details:

              Giiant Pharma already initiated its IND-enabling preclinical program with its lead candidate, GT-2108, for the treatment of moderate-to-severe ulcerative colitis. This additional financing will support the development of GT-2108 up to clinical Phase 1b completion.

              Lead Product(s): GT-2108

              Therapeutic Area: Gastroenterology Product Name: GT-2108

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Amplitude Ventures

              Deal Size: $1.2 million Upfront Cash: Undisclosed

              Deal Type: Financing June 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Giiant pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Giiant Pharma inc Announced the Closing of US$11M in Seed Financing

              Details:

              The Company has identified GT-2108 as a lead candidate for the treatment of inflammatory bowel diseases (IBD). GT-2108 is an orally-administered, colon-specific PDE4 inhibitor prodrug with potent anti-inflammatory properties.

              Lead Product(s): GT-2108

              Therapeutic Area: Gastroenterology Product Name: GT-2108

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Amplitude Ventures

              Deal Size: $11.0 million Upfront Cash: Undisclosed

              Deal Type: Financing May 19, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY